Dispensation Channels of Anti-TNFs in Inflammatory Bowel Disease

Dispensation Channels of Anti-TNFs in Inflammatory Bowel Disease

2013 Value in health

Thivolet, M. | Remuzat, C. | Kornfeld, A. | Toumi, M. | Volume: 16, Issue: 7, Pages: A501, D,

In The Netherlands, the funding for some high cost drugs and particularly biologics was transferred in 2012 to hospital pharmacy dispensation channel. A European study forecast (2012-2016) shown hospital dispensation as a very effective policy to reduce budget impact of branded biologics and increase savings related to biosimilars. Two biologics (anti-TNFs) are indicated for Inflammatory Bowel Disease (IBD) in EU with different mode of administration: infliximab (Intravenous) and adalimumab (Subcutaneous).